Phase 2 N=73 Optimization of IV Ketamine for Treatment Resistant Depression
Major Depressive Disorder (MDD) · Treatment Resistant Depression (TRD)
Primary: MADRS — 14.77; 22.72 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=240 Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
Retinitis Pigmentosa
Primary: Central Visual Field (vf) Change Assessed Using the 30-2 Program of the Humphrey Field Analyzer (HFA). — -51.5; -49.6 annual change in db vf sensitivity — p=0.66
Phase 4 N=61 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
Non-Hodgkin's Lymphoma
Primary: Proportion of Patients Who Achieved at Least 5*10^6 Cluster of Differentiation 34+ (CD34+) Cells Per Kilogram (Cells/kg) — 60.0; 54.8 percentage of participants — p=0.395
Phase 3 N=724 A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 — 71; 64 Percentage of participants — p=0.030
Phase 3 N=162 A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema
Cirrhosis
Primary: Body ｗeight — -1.95; -0.44 Kg — p=<0.0001
Phase 3 N=40 A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema
Cirrhosis
Primary: Body Weight — -1.14; -1.37 kg
Phase 2 N=47 Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder
PTSD
Primary: Changes in CAPS Scores. — 43.5; 51.1 scores on a scale
Phase 2 N=112 Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Prostate Adenocarcinoma · Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Number of Participants Progression-free at 18 Months — 0 participants
Phase 2 N=49 Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer
Head and Neck Cancer · Radiation Toxicity · Xerostomia
Primary: Number of Patients Scored as Having the Surgical Technique of Submandibular Salivary Gland Transfer Performed "Per Protocol" — 34 participants
Phase 4 N=1,798 Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT
Uterine Atony · Postpartum Hemorrhage
Primary: Number of Subjects Reporting Uterine Atony or Postpartum Hemorrhage Requiring Medical (Medication or Blood Transfusion), Surgical or Other Interventional Treatment — 45…
N/A N=5,271 Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia
Pneumonia
Primary: Time to 30-day Mortality — 15; 14 days
N/A N=54 Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory
Posttraumatic Stress Disorder
Primary: Clinician Administered Posttraumatic Stress Disorder Scale (CAPS) — 72.13; 70.63; 58.27; 64.54 scores on a scale — p=>0.05
Phase 3 N=322 Nicotine Mouth Film for Craving Relief.
Smoking Cessation
Primary: The Change From Pre-dose Post-provocation in Craving Score at 50 Seconds — -14.15; -9.26 mm — p=0.0141
Phase 2 N=41 Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Define the Maximum Tolerated Dose (MTD) Using This Dose Schedule. — 20; 28.6; 33.3 Percentage subj w dose limiting toxicity
N/A N=4,658 International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)
Atrial Fibrillation
Primary: Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) — 1.3; 1.6; 1.4; 2.3 Percentage of Participants